medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2014, Number 02

<< Back Next >>

Ginecol Obstet Mex 2014; 82 (02)

Intrauterine contraception in nulliparous women as a strategy to reduce unplanned pregnancies in Latin America

Lira-Plasencia J, Bahamondes L, Bahamondes MV, Fugarolas JM, Kosoy G, Magalhaes J, Paez-Fonseca B, Perfumo PR

Language: Spanish
References: 78
Page: 111-122
PDF size: 853.75 Kb.


ABSTRACT

Due high rates of unplanned pregnancy and unsafe abortion in young women in Latin America intrauterine contraception, by its great contraceptive efficacy, should be offered by the public services of health in a more generalized way. However, some negative prejudices prevail over the perception of its benefits. The aim of this article was to explore the most relevant myths around this contraceptive method in Latin America and make a review of the literature to allay the fears of their use by young and nulliparous women.
Methods: Descriptive and retrospective study. Search for information in Embase and PubMed with emphasis on clinical randomized studies, studies of cases and controls, meta-analyses and systematic reviews which show risks and benefits of intrauterine contraception.
Results: Evidence shows that intrauterine contraception has few contraindications for young women and nulliparous; for this reason it must be as an effective public health strategy to reduce unplanned pregnancies and unsafe abortions.
Conclusions: We identified the major barriers to the use of intrauterine contraception in Latin America and evidence for each one of them in the bibliography. Doctors of first contact in health systems should now recognize that intrauterine contraception is safe and effective.


REFERENCES

  1. United Nations. Economic and Social Council. Adolescents and youth. January 2012. Disponible en: http://www.un.org/esa/population/cpd/cpd2012/E. CN.9.2012.4Adolescents-and-youthAdvance%20Unedited% 20Copy.pdf. Consultado en agosto de 2013. Nivel de evidencia III.

  2. United Nations Expert Group Meeting on Adolescentes, Youth and Development. High adolescent fertility in the context of declining fertility in Latin America. July 2011. http://www.un.org/esa/population/meetings/egmadolescents/ p01 Consultado en agosto de 2013. Nivel de evidencia III.

  3. 3.- The National Campaing to Prevent Teen and Unplanned Pregnancy. Teen Sexual Activity, Pregnancy and Childbearing among Latinos in the United States, fact sheet june 2006. http://www.thenationalcampaign.org/resources/ pdf/Latinos2006.pdf. Consultado en agosto 2013. Nivel de evidencia III.

  4. United Nation. World Contraceptive Use 2011. Disponible en: http://www.un.org/esa/population/publications/contraceptive2011/ wallchart front.pdf. Consultado en agosto de 2013.

  5. In Brief. Facts on Investing in Family Planning and Maternal and Newborn Health. Latin America and the Caribbean- Update November 2010. Guttmacher Institute In Brief. http://www.guttmacher.org/pubs/FB-AIU-LAC.pdf. Consultado en agosto 2013. Nivel de evidencia III.

  6. Sedgh G, Henshaw S, Singh S, Ahman E, Shah IH. Induced abortion: estimated rates and trends wordlwide. Lancet 2007;370:1338-1345. Nivel de evidencia III.

  7. Hubacher D, Finer L, Espey E. Renewed interest in intrauterine contraception in the United States: evidence and explanation. Contraception 2011;83:291-294. Nivel de evidencia III.

  8. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth J, Secura G. Effectiveness of long-acting reversible contraception. N Engl J Med 2012;366:1998-2007. Nivel de evidencia II-1.

  9. Long-acting reversible contraception: implants and intrauterine devices. Practice Bulletin No. 121. American College of Obstetricians and Gynecologists. Obstet Gynecol 2011;118:184-196. Nivel de evidencia III.

  10. Lyus R, Lohr P, Prager S. Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. Contraception 2010;81:367-371. Nivel de evidencia III.

  11. World Health Organizaron. Medical eligibility criteria for contraceptive use. 4th ed. Geneva: WHO; 2009. Disponible en: http://whqlibdoc.who.int/publications/ 2010/9789241563888 Consultado en agosto de 2013. Nivel de evidencia III.

  12. Tyler CP, Whiteman MK, Zapata LB, Curtis KM, Hilla SD, Machbanks PA. Health care provider attitudes and practices related to intrauterine devices for nulliparous women. Obstet Gynecol 2012;119:762-771. Nivel de evidencia II-3.

  13. Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397-404. Nivel de evidencia III.

  14. Marions L, Lovkvist L, Taube A, Johansson M, Dalvik H, Overlie I. Use of the levonorgestrel releasing intrauterine system in nulliparous women - a non-interventional study in Sweden. Eur J Contraception and Reprod Health Care 2011;16:126-134. Nivel de evidencia III.

  15. Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception 2004;69:407-412. Nivel de evidencia II-2.

  16. Bahamondes MV, Hidalgo MM, Bahamondes L, Monteiro I. Ease of insertion and clinical performance of the levonorgestrel- releasing intrauterine system in nulligravidas. Contraception 2011;84:e11-e16. Nivel de evidencia II-1.

  17. Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenber D, Secura G. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011;117:1105- 1113. Nivel de evidencia II-1.

  18. Hubacher D, Reyes V, Lillo S, Zepeda A, Chen PL, Croxatto H. Pain from copper intrauterine device insertion: randomized trial of prophylactic ibuprofen. Am J Obstet Gynecol 2006;195:1272-1277. Nivel de evidencia I.

  19. Chi IC, Galich LF, Tauber PF, et al. Severe pain at interval IUD insertion: a case-control analysis of patient risk factors. Contraception 1986;34:483-495. Nivel de evidencia II-2.

  20. Karabayirli S, Ayrim AA, Muslu B. Comparision of the analgesic effects of oral tramadol and naproxen sodium on pain relief during IUD insertion. J Min Invasive Gynecol 2012;19:581-584. Nivel de evidencia I.

  21. McNicholas CP, Madden T, Zhao Q, Secura G, Allsworth JE, Peipert JF. Cervical lídocaine for IUD insertional pain: a randomized controlled trial. Am J Obstet Gynecol 2012;207:384. Nivel de evidencia I.

  22. Maguire K, Davis A, Rosario Tejeda L, Wethoff C. Intracervical lídocaine gel for intrauterine device insertion: a randomized controlled trial. Contraception 2012; 86: 214-219. Nivel de evidencia I.

  23. Chor J, Bregand-White J, Golobof A, Harwood B, Cowett A. Ibuprofen prophylaxis for levonorgestrel-releasing intrauterine system insertion: a randomized controlled trial. Contraception 2012;85:558-562. Nivel de evidencia I.

  24. Heikinheimo O, Inki P, Kunz M, Parmhed S, Anttila AM, Olsson SE, Hurskainen R, Gemzell-Danielsson K. Doubleblind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel releasing intrauterine system. Contraception 2010;81:481-486. Nivel de evidencia I.

  25. Dijkhuizen K, Dekkers OM, Holleboom CA, de Groot CJ, Hellebrekers BW, van Roosmalen GJ, et al. Vaginal misoprostol prior to insertion of an intrauterine device: an RCT. Hum Reprod 2011;26:323-329. Nivel de evidencia I.

  26. Wellings K, Zhihong Z, Krentel A, Barretta G, Glasier A. Altitudes towards long-acting reversible methods of contraception in general practice in the UK. Contraception 2007;76:208-214. Nivel de evidencia III.

  27. Stanwood NL, Garrett JM, Konrad TR. Obstetrician-gynecologists and the intrauterine device: a survey of attitudes and practice. Obstet Gynecol 2002;99:275-280. Nivel de evidencia III.

  28. Black KL, Sakhaei T, Garland SM. A study investigating obstetricians’ and gynaecologists’ management of women requesting an intrauterine device. Aust N Z J Obstet Gynaecol 2010;50:184-188. Nivel de evidencia III.

  29. http://www.paragard.com/healthcareprofessional/qlobal/ pdf/Prescribing- lnfo.pdf. Consultado en agosto 2010.

  30. http://berlex.bayerhealthcare.com/html/products/pi/ MirenaPl.pdf. Consultado en agosto 2013.

  31. Zhou L, Harrison-Woolrych M, Coulter DM. Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena). Pharmacoepidemiol Drug Saf 2003;12:371-377. Nivel de evidencia II-3.

  32. Bahamondes L, Díaz J, Marchi NM, Petta CA, Cristofoletti ML, Gómez G. Performance of copper intrauterine device when inserted after an expulsión. Hum Reprod 1995;10:2917-2918. Nivel de evidencia III.

  33. Merki-Feld GS, Schwarz D, Imthurn B, Keller PJ. Partial and complete expulsión of the Multiload 375 IUD and the levonorgestrel-releasing IUD after correct insertion. Eur J Obstet Gynecol Reprod Biol 2008;137:92-96. Nivel de evidencia III.

  34. Johnson BA. Insertion and removal of intrauterine devices. Am Fam Physician 2005;71:95-102. Nivel de evidencia III.

  35. Petersen KR, Brooks L, Jacobsen N, Skoby SO. Clinical performance of intrauterine devices in nulligravidae: is the length of endometrial cavity of significance? Acta Eur Fértil 1991;22:225-228. Nivel de evidencia I.

  36. O’Brien PA, Kulier R, Helmerhorst FM, Usher-Patel M, d’Arcangues C. Copper-containing, framed intrauterine devices for contraception: a systematic review of randomized controlled trials. Contraception 2008;77:318-327. Revisión sistemática.

  37. Faúndes A, Alvarez F, Díaz J. A Latin American experience with levonorgestrel IUD. Ann Med 1993;25:149-153. Nivel de evidencia III.

  38. Meirik O, Rowe PJ, Peregoudov A, Piaggio G, Petzold M; IUD Research Group at the UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction. The frameless copper IUD (GyneFix) and the TCu380A IUD: results of an 8-year multicenter randomized comparative trial. Contraception 2009;80:133-141. Nivel de evidencia I.

  39. Wu S, Hu J, Wildemeersch D. Performance of the frameless GyneFix and the TCu380A IUD in a 3-year multicenter, randomized, comparative trial in parous women. Contraception 2000;61:91-98. Nivel de evidencia III.

  40. Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. Contraception 2007;75(Suppl 6):S8-11. Nivel de evidencia III.

  41. Mishell DR Jr, Israel R, Freid N. A study of the copper T intrauterine contraceptive device (TCu 200) in nulliparous women. Am J Obstet Gynecol 1973;116:1092-1096.

  42. Bahamondes MV, Monteiro I, Canteiro R, Femandes Ados, Bahamondes L. Length of the endometrial cavity and intrauterine contraceptive expulsión. Int J Gynaecol Obstet 2011;113:50-53. Nivel de evidencia II-2.

  43. Canteiro R, Bahamondes MV, dosSantos Fernandes A, Espejo-Arce X, Marchi NM, Bahamondes L. Length of the endometrial cavity as measured by uterine sounding and ultrasonography in women of different parities. Contraception 2010;81:515-519. Nivel de evidencia II-2.

  44. Monteiro I, Bhamondes L, Diaz J, Perrotti M, Petta C. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study. Contraception 2002; 65: 325-328. Nivel de evidencia III.

  45. Middleton AJ, Naish J, Singer N. General practiitioners’ views on the use of the levonorgestrel-releasing intrauterine system in young, nulligravid women, in London, UK. Eur J Contracept Reprod Health Care 2011;16:311-318. Nivel de evidencia III.

  46. Stanwood NL, Garrett JM, Konrad TR. Obstetrician Gynecologists and intrauterine device: A survey of attitudes and practice. Obstet Gybecol 2002;99:275-280. Nivel de evidencia III.

  47. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:785-788. Nivel de evidencia III.

  48. National Institute for Health and Clinical Excellence. Clinical Guideline 30: long-acting reversible contraception, developed by the National Collaborating Centre for Women’s and Children’s Health, October 2005. Disponible en: http://www.nice.orq.uk/nicemedia/ live/10974/29909/29909.pdf. Consultado en agosto 2013. Guía de Practica Clínica.

  49. Mohllajee AP, Curtís KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception 2006;73:145-153. Revisión sistemática.

  50. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid womwn. N Engl J Med 2001;345:561-567. Nivel de evidencia II-2.

  51. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000;356:1013-1019. Revisión sistemática.

  52. Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years’ comparative experience of levonorgestrel and copper-releasing intrauterine devices. Obstet Gynecol 1991;77:261-264. Nivel de evidencia II-2.

  53. Cox M, Tripp J, Blacksell S. Clinical performance of the levonorgestrel intrauterine system in routine use by th UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care 2002;28:73-77. Nivel de evidencia III.

  54. Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Committe Opinión No. 450. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;114:1434-1438. Nivel de evidencia III.

  55. Adolescents and Long-Acting Reversible Contraception: implants and intrauterine devices. Committe Opinión No. 539. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;120:983-988. Nivel de evidencia III.

  56. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol 1999;181:1263-1269. Nivel de evidencia III.

  57. Backman T. Benefit-risk assessment of the levonorgestrel intrauterine system in contraception. Drug Saf 2004;27:1185-1204. Nivel de evidencia III.

  58. Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrelreleasing intrauterine device. Ann Med 1990; 22: 85-90. Nivel de evidencia III.

  59. Lewis RA, Taylor D, Natavio MF, Melamed A, Félix J, Mishell D Jr. Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability. Contraception 2010;82:491-496. Nivel de evidencia II-2.

  60. Jones RL, Critchley HO. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Human Reprod 2000;15(Suppl 3):162-172. Nivel de evidencia III.

  61. Mandelin E, Koistinen H, Koistinen R, Affandi B, Seppala M. Levonorgestrel-releasing intrauterine device-wearing women express contraceptive glycodelin A in endometrium during midcycle: another contraceptive mechanism? Human Reprod 1997;12:2671-2675. Nivel de evidencia III.

  62. Natavio MF, Taylor D, Lewis RA, Blumenthal P, Félix JC, Melamed A, Gentzschein E, Stanczyk FZ, Mishell RD. Temporal changes in cervical mucus after insertion of the levonorgestrel-releasing intrauterine system. Contraception 2013;87:426-31. Nivel de evidencia III.

  63. World Health Organization. Mechanism of action, safety and efficacy of intrauterine devices. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1987;753:1- 91. Nivel de evidencia III.

  64. Stanford JB, Mikolajcyk RT. Mechanisms of action of intrauterine devices: Update and estimation of post-fertilization effects. Am J Obstet Gynecol 2002;187:1699-1708. Nivel de evidencia III.

  65. Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility follow -up after participation in a randomized clinical trial. Contraception 2007;75:88-92. Nivel de evidencia III.

  66. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. Centers for Disease Control and Prevention (CDC) [published erratum appers in MMWR Morb Mortal Wkly Rep 2011;60:18]. MMWR Recomm Rep 2010 (RR-12);59:1-110. Nivel de evidencia II-3.

  67. U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep 2010;59(RR-4):1-86. Nivel de evidencia II-2.

  68. Grimes DA, López LM, Schulz KF. Antibiotic prophylaxis for intrauterine contracptive device insertion. Cochrane Database Syst Rev. 2001, Issue 3. Art. No.: CD001327. DOI: 10.1002/14651858.CD001327. Revisión sistemática.

  69. Centers for Disease Control and Prevention (CDC). Ectopic pregnancy— United States, 1990-1992. MMWR Morb Mortal Wkly Rep. 1995 Jan 27;44:46-8. Nivel de evidencia II-3.

  70. Kamwendo F, Forslin L, Bodin L, Danielsson D. Epidemiology of ectopic pregnancy during a 28 year period and the role of pelvic inflammatory disease. Sex Transm Infect 2000;76:28. Nivel de evidencia III.

  71. Skjeldestad FE. How effectively do copper intrauterine devices prevent ectopic pregnancy? Acta Obstet Gynecol Scand 1997;76:684-90. Nivel de evidencia II-2.

  72. Backman T, Rauramo I, Huhtala S, Koskenvuo M. Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol 2004;190:50-54. Nivel de evidencia III.

  73. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) lUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56- 72. Nivel de evidencia I.

  74. Mansour D, Gemzell-Danielsson K, Inki P, Jensen JT. Fertility after discontinuation of contraception: a comprehensive review of the literature. Contraception 2011;84:465-477. Nivel de evidencia III.

  75. Xiong X, Buekens P, Wollast E. IUD use and the risk of ectopic pregnancy: a meta-analysis of case-control studies. Contraception 1995;52:23-34. Metanálisis.

  76. Bahamondes L, Petta CA, Fernandes A, Monteiro I. Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. Contraception 2007;75(Suppl 6):S134- 9. Nivel de evidencia III.

  77. Aslam N, Blunt S. Latthe P. Effectiveness and tolerability of levonorgestrel intrauterine system in adolescents. J Obstet Gynecol 2010;30:489-91. Nivel de evidencia III.

  78. Kaunitz AM, Meredith S, Inki P, Kubba A, Sánchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 2009;113:1104- 16. Revisión sistemática.




2020     |     www.medigraphic.com